Tamoxifen, cytochrome P450 genes and breast cancer clinical outcomes

Breast

Volumn 20, Issue 2, 2011, Pages 111-118

  Singh, Madhu S ^a   Francis, Prudence A ^b   Michael, Michael ^b  

^a Andrew Love Cancer Centre   (Australia)

^b PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

Breast cancer; CYP2D6; Cytochrome P450; Tamoxifen

Indexed keywords

ANASTROZOLE; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; CITALOPRAM; CYTOCHROME P450; CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; CYTOCHROME P450 1B1; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; CYTOCHROME P450 3A7; DRUG METABOLITE; EFAVIRENZ; ESTROGEN RECEPTOR; EXEMESTANE; FLUOXETINE; FLUOXYMESTERONE; HORMONE RECEPTOR; NEVIRAPINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; TAMOXIFEN;

BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GENETICS; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG METABOLISM; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; ENZYME ACTIVITY; GENE EXPRESSION REGULATION; GENE FREQUENCY; GENETIC VARIABILITY; HOMOZYGOSITY; HOT FLUSH; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; METASTASIS; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PRIMARY TUMOR; PRIORITY JOURNAL; RECURRENT CANCER; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; STRUCTURE ACTIVITY RELATION; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

EID: 79952623482     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.breast.2010.11.003     Document Type: Review

References (62)

1. Arteaga C.L., Osborne C.K. Growth factors as mediators of estrogen/antiestrogen action in human breast cancer cells. Cancer Treat Res 1991, 53:289-304.
2. Ellis P.A., Saccani-Jotti G., Clarke R., Johnston S.R., Anderson E., Howell A., et al. Induction of apoptosis by tamoxifen and ICI 182780 in primary breast cancer. Int J Cancer 1997, 72:608-613.
3. Colleoni M., Gelber S., Goldhirsch A., Aebi S., Castiglione-Gertsch M., Price K.N., et al. Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93. J Clin Oncol 2006, 24:1332-1341.
4. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005, 365:1687-1717.
5. Fisher B., Costantino J.P., Wickerham D.L., Cecchini R.S., Cronin W.M., Robidoux A., et al. Tamoxifen for the prevention of breast cancer: current status of the national surgical adjuvant breast and bowel project P-1 study. J Natl Cancer Inst 2005, 97:1652-1662.
6. Fisher B., Dignam J., Wolmark N., Wickerham D.L., Fisher E.R., Mamounas E., et al. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet 1999, 353:1993-2000.
7. Howell A., Cuzick J., Baum M., Buzdar A., Dowsett M., Forbes J.F., et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005, 365:60-62.
8. Thurlimann B., Keshaviah A., Coates A.S., Mouridsen H., Mauriac L., Forbes J.F., et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005, 353:2747-2757.
9. Higgins M.J., Stearns V. Understanding resistance to tamoxifen in hormone receptor-positive breast cancer. Clin Chem 2009, 55:1453-1455.
10. Hull D.F., Clark G.M., Osborne C.K., Chamness G.C., Knight W.A., McGuire W.L., et al. Multiple estrogen receptor assays in human breast cancer. Cancer Res 1983, 43:413-416.
11. Ingle J.N., Krook J.E., Green S.J., Kubista T.P., Everson L.K., Ahmann D.L., et al. Randomized trial of bilateral oophorectomy versus tamoxifen in premenopausal women with metastatic breast cancer. J Clin Oncol 1986, 4:178-185.
12. Wiebe V.J., Osborne C.K., Fuqua S.A., DeGregorio M.W. Tamoxifen resistance in breast cancer. Crit Rev Oncol Hematol 1993, 14:173-188.
13. Stearns V., Zhou Q., Davidson N.E. Epigenetic regulation as a new target for breast cancer therapy. Cancer Invest 2007, 25:659-665.
14. Rodriguez-Antona C., Ingelman-Sundberg M. Cytochrome P450 pharmacogenetics and cancer. Oncogene 2006, 25:1679-1691.
15. Singh M.S., Michael M. Role of xenobiotic metabolic enzymes in cancer epidemiology. Methods Mol Biol 2009, 472:243-264.
16. Fabian C., Tilzer L., Sternson L. Comparative binding affinities of tamoxifen, 4-hydroxytamoxifen, and desmethyltamoxifen for estrogen receptors isolated from human breast carcinoma: correlation with blood levels in patients with metastatic breast cancer. Biopharm Drug Dispos 1981, 2:381-390.
17. Johnson M.D., Zuo H., Lee K.H., Trebley J.P., Rae J.M., Weatherman R.V., et al. Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen. Breast Cancer Res Treat 2004, 85:151-159.
18. Lim Y.C., Desta Z., Flockhart D.A., Skaar T.C. Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen. Cancer Chemother Pharmacol 2005, 55:471-478.
19. Stearns V., Johnson M.D., Rae J.M., Morocho A., Novielli A., Bhargava P., et al. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst 2003, 95:1758-1764.
20. Boocock D.J., Brown K., Gibbs A.H., Sanchez E., Turteltaub K.W., White I.N. Identification of human CYP forms involved in the activation of tamoxifen and irreversible binding to DNA. Carcinogenesis 2002, 23:1897-1901.
21. Crewe H.K., Notley L.M., Wunsch R.M., Lennard M.S., Gillam E.M. Metabolism of tamoxifen by recombinant human cytochrome P450 enzymes: formation of the 4-hydroxy, 4'-hydroxy and N-desmethyl metabolites and isomerization of trans-4-hydroxytamoxifen. Drug Metab Dispos 2002, 30:869-874.
22. Desta Z., Ward B.A., Soukhova N.V., Flockhart D.A. Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther 2004, 310:1062-1075.
23. Coller J.K., Krebsfaenger N., Klein K., Endrizzi K., Wolbold R., Lang T., et al. The influence of CYP2B6, CYP2C9 and CYP2D6 genotypes on the formation of the potent antioestrogen Z-4-hydroxy-tamoxifen in human liver. Br J Clin Pharmacol 2002, 54:157-167.
24. Gaedigk A., Blum M., Gaedigk R., Eichelbaum M., Meyer U.A. Deletion of the entire cytochrome P450 CYP2D6 gene as a cause of impaired drug metabolism in poor metabolizers of the debrisoquine/sparteine polymorphism. Am J Hum Genet 1991, 48:943-950.
25. Bradford L.D. CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics 2002, 3:229-243.
26. Zanger U.M., Raimundo S., Eichelbaum M. Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn Schmiedebergs Arch Pharmacol 2004, 369:23-37.
27. Beverage J.N., Sissung T.M., Sion A.M., Danesi R., Figg W.D. CYP2D6 polymorphisms and the impact on tamoxifen therapy. J Pharm Sci 2007, 96:2224-2231.
28. Jin Y., Desta Z., Stearns V., Ward B., Ho H., Lee K.H., et al. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst 2005, 97:30-39.
29. Goetz M.P., Rae J.M., Suman V.J., Safgren S.L., Ames M.M., Visscher D.W., et al. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol 2005, 23:9312-9318.
30. Rotger M., Colombo S., Furrer H., Bleiber G., Buclin T., Lee B.L., et al. Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients. Pharmacogenet Genomics 2005, 15:1-5.
31. Zanger U.M., Turpeinen M., Klein K., Schwab M. Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation. Anal Bioanal Chem 2008, 392:1093-1108.
32. Finta C., Zaphiropoulos P.G. The human cytochrome P450 3A locus. Gene evolution by capture of downstream exons. Gene 2000, 260:13-23.
33. Kuehl P., Zhang J., Lin Y., Lamba J., Assem M., Schuetz J., et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001, 27:383-391.
34. Schuetz E.G., Relling M.V., Kishi S., Yang W., Das S., Chen P., et al. PharmGKB update: II. CYP3A5, cytochrome P450, family 3, subfamily A, polypeptide 5. Pharmacol Rev 2004, 56:159.
35. Wegman P., Elingarami S., Carstensen J., Stal O., Nordenskjold B., Wingren S. Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer. Breast Cancer Res 2007, 9. R7.
36. Tucker A.N., Tkaczuk K.A., Lewis L.M., Tomic D., Lim C.K., Flaws J.A. Polymorphisms in cytochrome P4503A5 (CYP3A5) may be associated with race and tumor characteristics, but not metabolism and side effects of tamoxifen in breast cancer patients. Cancer Lett 2005, 217:61-72.
37. Williams J.A., Ring B.J., Cantrell V.E., Jones D.R., Eckstein J., Ruterbories K., et al. Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7. Drug Metab Dispos 2002, 30:883-891.
38. Desta Z., Zhao X., Shin J.G., Flockhart D.A. Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet 2002, 41:913-958.
39. Sim S.C., Risinger C., Dahl M.L., Aklillu E., Christensen M., Bertilsson L., et al. A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther 2006, 79:103-113.
40. Schroth W., Antoniadou L., Fritz P., Schwab M., Muerdter T., Zanger U.M., et al. Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. J Clin Oncol 2007, 25:5187-5193.
41. Okishiro M., Taguchi T., Jin Kim S., Shimazu K., Tamaki Y., Noguchi S. Genetic polymorphisms of CYP2D6 10 and CYP2C19 2, 3 are not associated with prognosis, endometrial thickness, or bone mineral density in Japanese breast cancer patients treated with adjuvant tamoxifen. Cancer 2009, 115:952-961.
42. Rae J.M., Sikora M.J., Henry N.L., Li L., Kim S., Oesterreich S., et al. Cytochrome P450 2D6 activity predicts discontinuation of tamoxifen therapy in breast cancer patients. Pharmacogenomics J 2009, 9:258-264.
43. Rae J.M. Cytochrome P450 2D6 activity predicts adherence to tamoxifen therapy (anstract). Breast Cancer Research Treatment 2007, 106.
44. Cuzick J., Sestak I., Cella D., Fallowfield L. Treatment-emergent endocrine symptoms and the risk of breast cancer recurrence: a retrospective analysis of the ATAC trial. Lancet Oncol 2008, 9:1143-1148.
45. Kiyotani K., Mushiroda T., Sasa M., Bando Y., Sumitomo I., Hosono N., et al. Impact of CYP2D6*10 on recurrence-free survival in breast cancer patients receiving adjuvant tamoxifen therapy. Cancer Sci 2008, 99:995-999.
46. Xu Y., Sun Y., Yao L., Shi L., Wu Y., Ouyang T., et al. Association between CYP2D6*10 genotype and survival of breast cancer patients receiving tamoxifen treatment. Ann Oncol 2008, 19:1423-1429.
47. Lim H.S., Ju Lee H., Seok Lee K., Sook Lee E., Jang I.J., et al. Clinical implications of CYP2D6 genotypes predictive of tamoxifen pharmacokinetics in metastatic breast cancer. J Clin Oncol 2007, 25:3837-3845.
48. Schroth W., Goetz M.P., Hamann U., Fasching P.A., Schmidt M., Winter S., et al. Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. Jama 2009, 302:1429-1436.
49. Kiyotani K, Mushiroda T, Imamura CK, Hosono N, Tsunoda T, Kubo M, et al. Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients. J Clin Oncol.
50. Newman W.G., Hadfield K.D., Latif A., Roberts S.A., Shenton A., McHague C., et al. Impaired tamoxifen metabolism reduces survival in familial breast cancer patients. Clin Cancer Res 2008, 14:5913-5918.
51. Ramón y Cajal T., Altes A., Pare L., del Rio E., Alonso C., Barnadas A., et al. Impact of CYP2D6 polymorphisms in tamoxifen adjuvant breast cancer treatment. Breast Cancer Res Treat 2010, 119:33-38.
52. Bijl M.J., van Schaik R.H., Lammers L.A., Hofman A., Vulto A.G., van Gelder T., et al. The CYP2D6*4 polymorphism affects breast cancer survival in tamoxifen users. Breast Cancer Res Treat 2009, 118:125-130.
53. Wegman P., Vainikka L., Stal O., Nordenskjold B., Skoog L., Rutqvist L.E., et al. Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients. Breast Cancer Res 2005, 7:R284-R290.
54. Rutqvist L.E., Cedermark B., Glas U., Johansson H., Rotstein S., Skoog L., et al. Radiotherapy, chemotherapy, and tamoxifen as adjuncts to surgery in early breast cancer: a summary of three randomized trials. Int J Radiat Oncol Biol Phys 1989, 16:629-639.
55. Nowell S.A., Ahn J., Rae J.M., Scheys J.O., Trovato A., Sweeney C., et al. Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients. Breast Cancer Res Treat 2005, 91:249-258.
56. Goetz MP. 2009.
57. Loprinzi C.L., Sloan J.A., Perez E.A., Quella S.K., Stella P.J., Mailliard J.A., et al. Phase III evaluation of fluoxetine for treatment of hot flashes. J Clin Oncol 2002, 20:1578-1583.
58. Goetz M.P., Knox S.K., Suman V.J., Rae J.M., Safgren S.L., Ames M.M., et al. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat 2007, 101:113-121.
59. Kelly CM, Juurlink DN, Gomes T, Duong-Hua M, Pritchard KI, Austin PC, et al. Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study. Bmj: 340: c693.
60. Lash T.L., Pedersen L., Cronin-Fenton D., Ahern T.P., Rosenberg C.L., Lunetta K.L., et al. Tamoxifen's protection against breast cancer recurrence is not reduced by concurrent use of the SSRI citalopram. Br J Cancer 2008, 99:616-621.
61. Heller T., Kirchheiner J., Armstrong V.W., Luthe H., Tzvetkov M., Brockmoller J., et al. AmpliChip CYP450 GeneChip: a new gene chip that allows rapid and accurate CYP2D6 genotyping. Ther Drug Monit 2006, 28:673-677.
62. Punglia R.S., Burstein H.J., Winer E.P., Weeks J.C. Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis. J Natl Cancer Inst 2008, 100:642-648.